Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis
2014 (English)In: Translational Proteomics, ISSN 2212-9634, Vol. 2, no 1, 14-24 p.Article in journal (Refereed) Published
There is a need for a better differentiation of aggressive tumors in prostate cancer to design a tailored treatment for each patient, preferably by a minimally invasive analysis of blood samples. In a previous study, we discovered a decrease of plasma levels of carnosine dipeptidase 1 (CNDP1) in association with aggressive prostate cancer. Now this relation has been investigated and characterized further by generating several new antibodies for extended analysis of CNDP1 in plasma. Multi-antibody sandwich assays were developed and applied to 1214 samples from two Swedish cohorts that confirmed decreased levels of CNDP1 in plasma from patients with advanced disease. Therein, data from CNDP1 assays allowed a better differentiation between tumor N stages than clinical tPSA, but did not when classifying T or M stages. Further investigations can now elucidate mechanisms behind decreasing levels of CNDP1 in plasma and primary in regards to lymph node metastasis.
Place, publisher, year, edition, pages
2014. Vol. 2, no 1, 14-24 p.
Carnosine dipeptidase 1, Plasma biomarker, Prostate cancer, Sandwich immunoassay, Suspension bead array
IdentifiersURN: urn:nbn:se:kth:diva-140795DOI: 10.1016/j.trprot.2013.12.001ScopusID: 2-s2.0-84891341787OAI: oai:DiVA.org:kth-140795DiVA: diva2:693090
QC 201402032014-02-032014-01-312014-02-03Bibliographically approved